NTSR1

NTSR1 is a G protein-coupled receptor for neurotensin whose distinct downstream effects can be separated by biasing signaling toward β-arrestin versus G protein pathways: the allosteric modulator SBI-553 acts as a β-arrestin-biased agonist while antagonizing neurotensin-driven G protein signaling, and this bias is sufficient to attenuate psychostimulant (cocaine) self-administration without the side effects of balanced agonism (PMID:32470395). In the basal ganglia, NTSR1 engages in antagonistic intramembrane receptor-receptor interactions with dopamine D2 receptors, with threshold neurotensin counteracting D2 agonist-induced inhibition of striatal dopamine and pallidal GABA release (PMID:16983483). In tumor contexts, NTS/NTSR1 signaling activates MAPK and NF-κB pathways and drives oncogenic programs: it triggers MMP1-mediated release of EGF-like ligands (HB-EGF, Neuregulin 1) that transactivate EGFR, HER2, and HER3 in lung cancer cells (PMID:25249545), forms a positive feedback loop with Wnt/β-catenin signaling in glioblastoma (PMID:29065410), and promotes invasion through a Jun→miR-494→SOCS6 axis (PMID:30261490). NTSR1 transcription is directly activated by the transcription factor TOX4, which is itself sequestered by the lncRNA SLCO4A1-AS1 (PMID:37726723). Genetic knockout studies indicate NTSR1 does not contribute substantially to neurotensin-mediated thermal nociception, a role instead attributable to NTSR2 (PMID:14725975).

1. 2004 Medium

   To define whether NTSR1 versus NTSR2 mediates neurotensin's antinociceptive effects, knockout mice resolved that NTSR1 is dispensable for thermal nociception, assigning that role to NTSR2.

   Evidence Ntsr1- and Ntsr2-deficient mice in hot plate, tail flick, and hind paw licking tests with in situ hybridization mapping

   PMID:14725975

   Open questions at the time

   • Negative result for NTSR1 does not exclude roles in non-thermal pain modalities
   • Does not address NTSR1 signaling mechanism in any pathway
2. 2006 Medium

   To test whether NTSR1 functionally modulates dopaminergic circuits, in vivo microdialysis showed NTSR1 antagonizes D2 receptor signaling through intramembrane receptor-receptor crosstalk at striatal terminals.

   Evidence Mono/dual-probe microdialysis in freely moving rats with NTSR1 antagonist SR48692

   PMID:16983483

   Open questions at the time

   • Molecular basis of the NTSR1/D2 heteromer not structurally defined
   • Single lab, pharmacological inference
3. 2012 Low

   To explore NTSR1 outside the nervous system, expression and functional assays placed NTSR1 in B lymphocytes where neurotensin promotes proliferation and survival.

   Evidence RT-PCR, western blot, and proliferation/apoptosis assays in human B cell lines and leukemia patient cells

   PMID:23109725

   Open questions at the time

   • Primarily expression characterization with limited NTSR1-specific mechanistic follow-up
   • Causal role of NTSR1 versus NTSR2 in B cell effects not disentangled
4. 2014 Medium

   To establish how NTSR1 drives epithelial tumor growth, lung cancer studies showed it transactivates EGFR/HER family receptors via MMP1-mediated EGF-like ligand release.

   Evidence siRNA knockdown, autocrine loop characterization, and erlotinib xenograft models in NTS/NTSR1-expressing lung cancer cells

   PMID:25249545

   Open questions at the time

   • Direct link between NTSR1 proximal signaling and MMP1 activation not detailed
   • Single lab
5. 2017 Medium

   To connect NTSR1 to developmental signaling in tumors, glioblastoma work identified a MAPK/NF-κB-driven positive feedback loop with Wnt/β-catenin.

   Evidence siRNA, pharmacological inhibition, gain-of-function, and xenograft assays with western blot/qPCR in glioblastoma lines

   PMID:29065410

   Open questions at the time

   • Mechanism linking NTSR1 to Wnt ligand induction not fully resolved
   • Single lab
6. 2018 Medium

   To define how NTSR1 promotes invasion, a defined NTSR1→Jun→miR-494→SOCS6 transcriptional/microRNA axis was mapped in glioblastoma.

   Evidence siRNA knockdown, ChIP, dual-luciferase reporter, invasion assays, and orthotopic xenografts

   PMID:30261490

   Open questions at the time

   • Proximal NTSR1 signaling events upstream of Jun not specified
   • Single lab
7. 2023 Medium

   To identify upstream control of NTSR1 expression, TOX4 was shown to be a direct transcriptional activator antagonized by the lncRNA SLCO4A1-AS1.

   Evidence RNA pull-down, RIP, ChIP, dual-luciferase reporter, migration/invasion assays, and tail vein metastasis model in lung cancer

   PMID:37726723

   Open questions at the time

   • Whether TOX4 regulation of NTSR1 operates outside lung cancer is unknown
   • Single lab
8. 2020 High

   To demonstrate that NTSR1 signaling pathways are pharmacologically separable, SBI-553 was characterized as a β-arrestin-biased modulator producing therapeutic effects on cocaine abuse distinct from balanced agonism.

   Evidence Biased agonism cell-based signaling assays and cocaine self-administration animal models

   PMID:32470395

   Open questions at the time

   • Structural basis of biased allosteric modulation not resolved here
   • In vivo target engagement beyond cocaine models not addressed

• How NTSR1's discrete G protein versus β-arrestin signaling branches map onto its diverse downstream effectors (D2 crosstalk, MMP1/EGFR transactivation, Wnt feedback, Jun/miR-494 axis) across tissues remains unresolved.
• No unified model linking signaling bias to specific oncogenic pathways
• Receptor-receptor heteromer structure undefined
• Tissue-specificity of TOX4-driven NTSR1 expression unknown